CHARLOTTE, N.C., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Premier, Inc. (NASDAQ:PINC), a leading healthcare improvement company, has named David Vorhoff senior vice president of corporate development and strategy.
Vorhoff, a 30-year investment banking veteran, is responsible for managing Premier’s strategic plan; establishing new business relationships to support corporate and enterprise unit objectives; overseeing merger and acquisition activities; and driving growth through product, service and business analysis. Vorhoff replaces Terry Linn, who recently retired.
“Dave’s extensive experience in corporate growth and development makes him a welcome addition to Premier,” said Susan DeVore, president and CEO, Premier. “We are thrilled to have him on board to drive strategic business practices that support long-term success for both Premier and our members.”
Prior to joining Premier, Vorhoff served as managing director of Deloitte Corporate Finance’s life sciences and healthcare group, which provides investment banking services. Vorhoff’s career has included functioning as president, managing director and co-founder at McColl Partners, LLC, an independent investment bank acquired by Deloitte. In addition, he previously worked in New York as managing director of Banc of America Securities in the global healthcare investment banking group, which later merged to become Bank of America Merrill Lynch.
“I am very excited to have the opportunity to work with Premier’s employees, members and partners to further develop and innovate its corporate strategy, as well as healthcare improvement overall,” said Vorhoff.
Vorhoff earned his bachelor’s and master’s degrees in business administration from the University of North Carolina at Chapel Hill. In addition, he has served on the board of directors of Sonic Automotive, Star Scientific and several private companies.
About Premier, Inc.
Premier, Inc. (NASDAQ:PINC) is a leading healthcare improvement company, uniting an alliance of approximately 3,600 U.S. hospitals and 120,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.
CONTACT: Morgan Guthrie, Premier, Inc.; [email protected]; 704.816.4152


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Apple Turns 50: From Garage Startup to AI Crossroads
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



